Impact of Intensive Lipid Lowering on Lipid Profiles Over Time and Tolerability in Stable Coronary Artery Disease: Insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)

Cardiovascular Therapeutics

Volumn 31, Issue 6, 2013, Pages 335-343

  Kawashiri, Masa aki ^a   Yamagishi, Masakazu ^a   Sakamoto, Tomohiro ^b   Takayama, Tadateru ^c   Hiro, Takafumi ^c   Daida, Hiroyuki ^d   Hirayama, Atsushi ^c   Saito, Satoshi ^e   Yamaguchi, Tetsu ^f   Matsuzaki, Masunori ^g  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Keiai Hospital   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Dyslipidemia; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Rosuvastatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTRAVASCULAR ULTRASOUND; JAPAN; JAPANESE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION;

CORONARY ARTERY DISEASE; DYSLIPIDEMIA; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84888356741     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12027     Document Type: Article

References (32)

1. Monthly Medical Information Express 2010, vol. 7. Tokyo: Elsevier, 2010.
2. Yamazaki T, Kurabayashi M; for the ASTRO-1 Study Group. A randomized controlled study to compare the effects of rosuvastatin 2.5 mg and pravastatin 10 mg on the plasma lipid profile in Japanese patients with hypercholesterolemia (ASTRO-1). Ann Vasc Dis 2009;2:148-158.
3. Ohbayashi H. Effect of rosuvastatin 2.5 mg on achieving lipid goals defined by the 2007 Japan atherosclerosis society guidelines. J Rural Med 2008;3:10-14.
4. Saku K, Zhang B, Noda K; for the PATROL Trial Investigation. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 2011;75:1493-1505.
5. Yamazaki T, Kurabayashi M; for the ASTRO-2 Study Group. A randomized controlled study to compare the effects of rosuvastatin 5 mg and atorvastatin 10 mg on the plasma lipid profile in Japanese patients with hypercholesterolemia (ASTRO-2). Ann Vasc Dis 2009;2: 159-173.
6. Mori Y, Kuriyama G, Tanaka T, Tajima N. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Endocrine 2009;36:412-418.
7. Takayama T, Hiro T, Yamagishi M, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009;73:2110-2117.
8. Takayama T, Hiro T, Masakazu Y, Daida H, Saito S, Yamaguchi T, Matsuzaki M for the COSMOS Investigators. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects). Circ J 2007;71:271-275.
9. Irie1 F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006;69:1264-1271.
10. Teramoto T, Kashiwagi A, Mabuchi H; for the J-LAP Investigators. Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: a study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res 2005;66:80-95.
11. Kurabayashi M, Yamazaki T, and the SUBARU Study Group. Superior benefit of aggressive lipid-lowering therapy for high-risk patients using statins: the SUBARU study-More hypercholesterolemic patients achieve Japan atherosclerosis society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb 2008;6:314-323.
12. Jones P, Davidson M, Stein E, et al. for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92:152-160.
13. Qin S, Koga T, Ganji S, Kamanna V, Kashyap M. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. Metabolism 2008;57:973-979.
14. Ooi E, Watts G, Nestel P, Sviridov D, Hoang A, Barrett P. Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab 2008;93:430-437.
15. Caslake MJ, Stewart G, Day SP, et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003;171:245-253.
16. Asztalos B, Maulf F, Dallal G, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007;99:681-685.
17. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297:499-508.
18. von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or =12 months) follow-up intravascular ultrasound. Circulation 2003;108:2757-2762.
19. Takarada S, Imanishi T, Ishibashi K, et al. The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome. JACC Cardiovasc Interv 2010;3:766-772.
20. Kimura T, Itoh T, Fusazaki T, et al. Low-density lipoprotein-cholesterol/high-density lipoprotein cholesterol ratio predicts lipid-rich coronary plaque in patients with coronary artery disease. Circ J 2010;74:1392-1398.
21. Johnsen S, Mathiesen E, Fosse E, Joakimsen O, Stensland-Bugge E, Njølstad I, Arnesen E. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression. Circulation 2005;112:498-504.
22. Katakami N, Kaneto H, Osonoi T, et al. Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients. Atherosclerosis 2011;214:442-447.
23. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-580.
24. Jensen MK, Rimm EB, Furtado JD, Sacks FM. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc 2012;1:e000232. doi:10.1161/JAHA.111.000232.
25. Ooi EM, Watts GF, Chan DC, Chen MM, Nestel PJ, Sviridov D, Barrett PHR. Dose-dependent effect of rosuvastatin on VLDL-Apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care 2008;31:1656-1661.
26. Lamendola C, Abbasi F, Chu JW, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol 2005;95:189-193.
27. Hunninghake DB, Stein EA, Bays HE, Rader DJ, Chitra RR, Simonson SG, Schneck DW. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 2004;15:115-123.
28. Wu Y, Wang Y, An C, Dong Z, Liu H, Zhang Y, An F. Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. Circ J 2012;76:1259-1266.
29. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
30. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
31. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-2564.
32. Shimojima M, Kawashiri MA, Nitta Y, et al. Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography. Am J Cardiovasc Dis 2012;2:84-88.